» Articles » PMID: 17337600

Dual Cardiac Contractile Effects of the Alpha2-AMPK Deletion in Low-flow Ischemia and Reperfusion

Abstract

Because the question "is AMP-activated protein kinase (AMPK) alpha(2)-isoform a friend or a foe in the protection of the myocardium against ischemia-reperfusion injury?" is still in debate, we studied the functional consequence of its deletion on the contractility, the energetics, and the respiration of the isolated perfused heart and characterized the response to low-flow ischemia and reperfusion with glucose and pyruvate as substrates. alpha(2)-AMPK deletion did not affect basal contractility, respiration, and high-energy phosphate contents but induced a twofold reduction in glycogen content and a threefold reduction in glucose uptake. Low-flow ischemia increased AMPK phosphorylation and stimulated glucose uptake and phosphorylation in both alpha(2)-knockout (alpha(2)-KO) and wild-type (WT) groups. The high sensitivity of alpha(2)-KO to the development of ischemic contracture was attributed to the constitutive impairment in glucose transport and glycogen content and not to a perturbation of the energy transfer by creatine kinase (CK). The functional coupling of MM-CK to myofibrillar ATPase and the CK fluxes were indeed similar in alpha(2)-KO and WT. Low-flow ischemia impaired CK flux by 50% in both strains, showing that alpha(2)-AMPK does not control CK activity. Despite the higher sensitivity to contracture, the postischemic contractility recovered to similar levels in both alpha(2)-KO and WT in the absence of fatty acids. In their presence, alpha(2)-AMPK deletion also accelerated the contracture but delayed postischemic contractile recovery. In conclusion, alpha(2)-AMPK is required for a normal glucose uptake and glycogen content, which protects the heart from the development of the ischemic contracture, but not for contractile recovery in the absence of fatty acids.

Citing Articles

Inhibition of PRKAA/AMPK (Ser485/491) phosphorylation by crizotinib induces cardiotoxicity via perturbing autophagosome-lysosome fusion.

Xu Z, Pan Z, Jin Y, Gao Z, Jiang F, Fu H Autophagy. 2023; 20(2):416-436.

PMID: 37733896 PMC: 10813574. DOI: 10.1080/15548627.2023.2259216.


Modulation of cardiac cAMP signaling by AMPK and its adjustments in pressure overload-induced myocardial dysfunction in rat and mouse.

Garnier A, Leroy J, Delomenie C, Mateo P, Viollet B, Veksler V PLoS One. 2023; 18(9):e0292015.

PMID: 37733758 PMC: 10513315. DOI: 10.1371/journal.pone.0292015.


Quantification and Proteomic Characterization of β-Hydroxybutyrylation Modification in the Hearts of AMPKα2 Knockout Mice.

Ding W, Li X, Tang C, Yang X, Sun Y, Song Y Mol Cell Proteomics. 2023; 22(2):100494.

PMID: 36621768 PMC: 9941199. DOI: 10.1016/j.mcpro.2023.100494.


Docosahexaenoic Acid-Enhanced Autophagic Flux Improves Cardiac Dysfunction after Myocardial Infarction by Targeting the AMPK/mTOR Signaling Pathway.

Shi Y, Li H, Wu T, Wang Q, Zhu Q, Guan X Oxid Med Cell Longev. 2022; 2022:1509421.

PMID: 35265261 PMC: 8898772. DOI: 10.1155/2022/1509421.


Role of Cardiac AMP-Activated Protein Kinase in a Non-pathological Setting: Evidence From Cardiomyocyte-Specific, Inducible AMP-Activated Protein Kinase α1α2-Knockout Mice.

Tokarska-Schlattner M, Kay L, Perret P, Isola R, Attia S, Lamarche F Front Cell Dev Biol. 2021; 9:731015.

PMID: 34733845 PMC: 8558539. DOI: 10.3389/fcell.2021.731015.